CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1

Beiping Miao, Zhaoqing Hu, Riccardo Mezzadra, Lotte Hoeijmakers, Astrid Fauster, Shangce Du, Zhi Yang, Melanie Sator-Schmitt, Helena Engel, Xueshen Li, Caroline Broderick, Guangzhi Jin, Raquel Gomez-Eerland, Lisette Rozeman, Xin Lei, Hitoshi Matsuo, Chen Yang, Ingrid Hofland, Dennis Peters, Annegien BroeksElke Laport, Annika Fitz, Xiyue Zhao, Mohamed A.A. Mahmoud, Xiujian Ma, Sandrine Sander, Hai kun Liu, Guoliang Cui, Yu Gan, Wei Wu, Yanling Xiao, Albert J.R. Heck, Wenxian Guan, Scott W. Lowe, Hugo M. Horlings, Cun Wang, Thijn R. Brummelkamp, Christian U. Blank, Ton N.M. Schumacher, Chong Sun

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

The dysregulated expression of immune checkpoint molecules enables cancer cells to evade immune destruction. While blockade of inhibitory immune checkpoints like PD-L1 forms the basis of current cancer immunotherapies, a deficiency in costimulatory signals can render these therapies futile. CD58, a costimulatory ligand, plays a crucial role in antitumor immune responses, but the mechanisms controlling its expression remain unclear. Using two systematic approaches, we reveal that CMTM6 positively regulates CD58 expression. Notably, CMTM6 interacts with both CD58 and PD-L1, maintaining the expression of these two immune checkpoint ligands with opposing functions. Functionally, the presence of CMTM6 and CD58 on tumor cells significantly affects T cell-tumor interactions and response to PD-L1−PD-1 blockade. Collectively, these findings provide fundamental insights into CD58 regulation, uncover a shared regulator of stimulatory and inhibitory immune checkpoints, and highlight the importance of tumor-intrinsic CMTM6 and CD58 expression in antitumor immune responses.

Original languageEnglish
Pages (from-to)1817-1828.e9
JournalCancer Cell
Volume41
Issue number10
DOIs
StatePublished - 9 Oct 2023

Fingerprint

Dive into the research topics of 'CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1'. Together they form a unique fingerprint.

Cite this